Clinical Trials Directory

Trials / Completed

CompletedNCT03033225

Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study

Phase II Study of EUS-Guided Verteporfin PDT in Solid Pancreatic Tumors (VERTPAC-02)

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
13 (actual)
Sponsor
Mayo Clinic · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This phase II trial studies how well ultrasound-guided verteporfin photodynamic therapy works for the treatment of patients with solid pancreatic tumors that cannot be removed by surgery (unresectable) or pancreatic cancer that has spread to other places in the body (advanced). Photodynamic therapy is a type of laser device that is guided by ultrasound imaging and used in combination with the drug verteporfin that may be less invasive and as effective as current treatment methods for patients with pancreatic cancer.

Detailed description

PRIMARY OBJECTIVE: I. To show that endoscopic ultrasound (EUS)-guided photodynamic therapy (PDT) to the pancreas is effective at direct ablation of advanced or locally advanced and small volume metastatic pancreatic tumors in a multicenter setting. SECONDARY OBJECTIVE: I. To evaluate the predictability of tumor necrosis as a function of delivered energy, based on pre-PDT contrast computed tomography (CT) scans. TERTIARY OBJECTIVE: I. Evaluate the safety of chemotherapy given two days after PDT. QUARTERNARY OBJECTIVE: I. Demonstrate that cancer biomarkers in pre- versus (vs.) post-PDT are surrogate markers of response. OUTLINE: Patients receive verteporfin intravenously (IV) and undergo fluorescence imaging and after 60 minutes undergo EUS-guided PDT. After completion of study treatment, patients are followed up at 14 days, and at 3, 6, and 12 months.

Conditions

Interventions

TypeNameDescription
PROCEDUREEndoscopic UltrasoundUndergo EUS-guided PDT
PROCEDUREFluorescence ImagingUndergo fluorescence imaging
DRUGPhotodynamic TherapyUndergo EUS-guided PDT
OTHERQuality-of-Life AssessmentAncillary studies
OTHERQuestionnaire AdministrationAncillary studies
DRUGVerteporfinGiven IV

Timeline

Start date
2017-05-31
Primary completion
2023-09-20
Completion
2023-09-20
First posted
2017-01-26
Last updated
2025-07-30
Results posted
2025-07-30

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03033225. Inclusion in this directory is not an endorsement.